Alzheimer's Association International Conference (Chicago, United States, July 22-26, 2018)

1: “Increased plasma BACE1 concentrations in women with subjective memory complaints: correlation with plasma NFL” P767-P768


2: “Correlations and altered longitudinal dynamics of plasma BACE1 and NFL concentrations in individuals with subjective memory complaints” P1036-P1037


3: “Innovative biomarker-guided diagnostic system from preclinical to Alzheimer’s disease dementia” P1510-P1511 
4: “Correlation of functional MRI connectomes with pathophysiological Alzheimer’s plasma biomarkers and risk factors in subjective memory complainers” P824-P825


5: “Correlation and longitudinal dynamics of plasma NFL and tau concentrations in amyloid-PET negative individuals with subjective memory complaints” P1036-P1037


6: “Increased longitudinal dynamics of plasma ykl-40 concentrations in amyloid-PET positive individuals with subjective memory complaints” P767-P768 

 


Clinical trials on Alzheimer’s disease (Barcelona, Spain, October 24-27, 2018) 

1: “Novel use of aptamer libraries for prediction of amyloid status from blood serum”

 

2: "Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers"

3: "A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers"

   Alzheimer’s Association International Conference (Los Angeles, United States, July 14-18, 2019)

1: “Sexual Dimorphism in Plasma Beta-Secretase 1 Concentrations in Cognitively Normal Individuals at Risk for AD: Cross-Sectional and Longitudinal Studies” 


2: “Plasma Beta-Secretase 1 Concentrations Predict Global and Regional Brain Burden of Amyloid-β in Cognitively Normal Individuals at Risk for AD: Cross-Sectional and Longitudinal Studies”


3: “Plasma Beta-Secretase 1 Concentrations Impact Plasma NFL Concentrations in Cognitively Normal Individuals at Risk for AD: Cross-Sectional and Longitudinal Studies”


4: “Biomarker-Guided Stratification Approach of the Clinical Continuum of Alzheimer’s Disease Using Unsupervised Clustering Methods” 


5: “Longitudinal Effect of Biological Variables on Plasma NFL and t-Tau Concentrations on Subjective Memory Complainers (INSIGHT-preAD-cohort): A 3-Year Follow-up Study” 


6: “Association between Brain Network Dynamics and Plasma Biomarkers in Cognitively Intact Individuals at Risk for Alzheimer’s Disease” 


7: “Combining Omics and Cognitive Tests Data from the Insight Pre-AD Study, Artificial Intelligence Technology Identifies Genomic Biomarkers for Early Detection of Alzheimer’s Disease” 


8: “Plasma Tau Is Associated with Basal Forebrain Rate of Atrophy in Older Adults at Risk of Alzheimer’s Disease” 


9: “Combining Omics and Imaging Data from the Insight Pre-AD Study, Artificial Intelligence Technology Identifies Genomic Biomarkers for Early Detection of Alzheimer’s Disease”